This Article Abstract Full Text Full Text (PDF) View Related Genuine Article on CVN View Online Appendix Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (12) Citing Articles via Google Scholar Google Scholar Articles by Berger, J. S. Articles by Becker, R. C. Search for Related Content PubMed Articles by Berger, J. S. Articles by Becker, R. C. Related Collections Related Article

Impact of Clopidogrel in Patients With Acute Coronary Syndromes Requiring Coronary Artery Bypass Surgery

A Multicenter Analysis

Jeffrey S. Berger, MD, MS^_*, Carla B. Frye, PharmD, Qing Harshaw, MD, PhD, Fred H. Edwards, MD, Steven R. Steinhubl, MD and Richard C. Becker, MD^_*,_*

^_* Division of Cardiology, Duke University School of Medicine, Duke Clinical Research Institute; Durham, North Carolina
EPI-Q, Inc., Oak Brook, Illinois
Department of Cardiothoracic Surgery, University of Florida, Jacksonville, Florida
Department of Cardiovascular Medicine, University of Kentucky, Lexington, Kentucky

View larger version (34K): [in this window] [in a new window] [Download PPT slide]   Figure 1 Study Population

View larger version (11K): [in this window] [in a new window] [Download PPT slide]   Figure 2 Incidence of Composite Outcome by Day Clopidogrel Stopped Before Surgery The composite outcome (reoperation or major bleeding) incidence is shown by day clopidogrel was stopped before surgery. The denominator for the points on this curve is the total number of patients who were exposed to clopidogrel 7 days (n = 329); 89 patients experienced the composite outcome. Red line = clopidogrel exposure.